| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tri-tert-butylphosphine tetrafluoroborate does not have biological targets; rather, it is a chemical catalyst ligand that targets transition metal centers, specifically palladium, in cross-coupling reaction mechanisms. Its biological relevance is indirect, as it facilitates the chemical synthesis of drug-like molecules but does not bind to proteins, enzymes, or receptors in living systems. In medicinal chemistry, the target of interest is the organic substrate being transformed, not the phosphine ligand itself.
|
|---|---|
| ln Vitro |
Tri-tert-butylphosphonium tetrafluoroborate is a ligand for the enantioselective α-arylation of N-boc-pyrrolidines, which is catalyzed by palladium. Suzuki cross-coupling reactions between aryl bromides and chlorides and palladium(0)-15-membered triene macrocycles have also employed it. Furthermore, it is employed in the Heck coupling of olefins with vinyl tosylate.
Tri-tert-butylphosphine tetrafluoroborate has no inherent in vitro biological activity, as it is a chemical reagent designed for organic synthesis rather than pharmacological intervention. It does not show cytotoxic, antiproliferative, or enzyme modulatory effects in standard cell-based assays. Any biological activity observed in the final products synthesized using this reagent is attributed to the elaborated drug molecule, not the ligand. It is not tested in cell viability or functional assays unless as a control for toxicity. The compound may be used in cellular studies indirectly for generating chemical libraries. |
| ln Vivo |
The compound has no in vivo biological activity of its own. It is not administered to animals for pharmacodynamic assessment. Any references to in vivo effects relate to molecules synthesized using it as a catalytic ligand, not the reagent itself. Toxicity studies in animals have not been performed for this reagent as a test article. Use as a reagent in PET tracer synthesis may produce radiolabeled compounds that are subsequently used in animal imaging studies.
|
| Enzyme Assay |
Tri-tert-butylphosphine tetrafluoroborate is not used in enzyme/receptor binding assays. Standard protocols involve its use as a catalyst component in chemical reactions. For a typical palladium-catalyzed Suzuki coupling, 2-5 mol% of the phosphine salt is combined with Pd2(dba)3 or Pd(OAc)2 in an inert atmosphere, mixed with aryl halide, boronic acid, and base (e.g., K2CO3 or Cs2CO3) in a solvent such as toluene or dioxane, and heated at 80-100degC for 12-24 hours. The reaction progress is monitored by TLC or HPLC.
|
| Cell Assay |
No cell-based protocols exist for Tri-tert-butylphosphine tetrafluoroborate. For cytotoxicity testing of synthesized compounds, typical protocols involve using the MTS or CellTiter-Glo assay. Cells are seeded in 96-well plates (5,000-10,000 cells/well) and treated with serial dilutions of the test compound for 48-72 hours. Viability is measured by absorbance at 490 nm (MTS) or luminescence (CellTiter-Glo). For the ligand itself, such assays are not performed.
|
| Animal Protocol |
No animal studies have been conducted with Tri-tert-butylphosphine tetrafluoroborate as a direct test compound. However, in vivo efficacy of molecules synthesized using this ligand is evaluated in xenograft or disease models. A typical protocol: Female BALB/c nude mice (6-8 weeks) are inoculated subcutaneously with tumor cells (5×10⁶). When tumors reach ~100 mm3, mice are randomized and treated orally or intraperitoneally with test compound daily for 2-4 weeks. Tumor volumes are measured twice weekly. The compound itself is not administered.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for Tri-tert-butylphosphine tetrafluoroborate. As a phosphonium salt (MW 290.13 g/mol), it is not intended for systemic exposure. If administered, it would likely undergo rapid decomposition or coordination to metal contaminants rather than standard ADME processes. No oral bioavailability, plasma half-life, volume of distribution, clearance, or metabolite identification data have been reported. The compound is stable as a solid under inert atmosphere but moisture-sensitive in solution.
|
| Toxicity/Toxicokinetics |
SDS indicates that Tri-tert-butylphosphine tetrafluoroborate may cause skin and eye irritation. The free phosphine is pyrophoric, but the tetrafluoroborate salt is air-stable and safer to handle. Acute oral toxicity is low (LD50 >2000 mg/kg predicted for salts). Inhalation of fine dust may cause respiratory irritation. Not classified as carcinogenic or mutagenic. Use with adequate ventilation and personal protective equipment (gloves, safety goggles). In case of contact, flush with water for 15 minutes.
|
| Additional Infomation |
Tri-tert-butylphosphine tetrafluoroborate has no clinical or regulatory approval status as a drug. It is a laboratory chemical reagent sold for research use only, not for human therapeutic administration. The compound is not listed in any pharmacopeia. It is not under clinical development for any indication. The only reported "other information" includes its utility in PET tracer synthesis via 11C-carbonylation reactions, enabling production of radiolabeled compounds for diagnostic imaging. It is also used in enantioselective alpha-arylation of N-Boc-pyrrolidines for chiral molecule synthesis.
|
| Molecular Formula |
C12H27P.BF4.H
|
|---|---|
| Molecular Weight |
290.13
|
| Exact Mass |
290.195
|
| CAS # |
131274-22-1
|
| PubChem CID |
2734635
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
261 °C(lit.)
|
| LogP |
6.163
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
147
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)[PH+](C(C)(C)C)C(C)(C)C.[B-](F)(F)(F)F
|
| InChi Key |
YTJUCJAUJCXFTN-UHFFFAOYSA-O
|
| InChi Code |
InChI=1S/C12H27P.BF4/c1-10(2,3)13(11(4,5)6)12(7,8)9;2-1(3,4)5/h1-9H3;/q;-1/p+1
|
| Chemical Name |
tritert-butylphosphanium;tetrafluoroborate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4467 mL | 17.2337 mL | 34.4673 mL | |
| 5 mM | 0.6893 mL | 3.4467 mL | 6.8935 mL | |
| 10 mM | 0.3447 mL | 1.7234 mL | 3.4467 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
